E
Eunice L. Kwak
Researcher at Harvard University
Publications - 148
Citations - 24080
Eunice L. Kwak is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & FOLFIRINOX. The author has an hindex of 49, co-authored 146 publications receiving 21705 citations.
Papers
More filters
Journal ArticleDOI
Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
Raymond C. Wadlow,Aram F. Hezel,Thomas A. Abrams,Lawrence S. Blaszkowsky,Charles S. Fuchs,Matthew H. Kulke,Eunice L. Kwak,Jeffrey A. Meyerhardt,David P. Ryan,Jackie Szymonifka,Brian M. Wolpin,Andrew X. Zhu,Jeffrey W. Clark +12 more
TL;DR: Panitumumab has minimal benefit in patients with KRAS wild-type metastatic colorectal cancer that has progressed on prior cetuximab.
Journal ArticleDOI
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
Jennifer A. Chan,Jason E. Faris,Janet E. Murphy,Lawrence S. Blaszkowsky,Eunice L. Kwak,Nadine Jackson McCleary,Charles S. Fuchs,Jeffrey A. Meyerhardt,Kimmie Ng,Andrew X. Zhu,Thomas A. Abrams,Brian M. Wolpin,Sui Zhang,Amanda Reardon,Bridget Fitzpatrick,Matthew H. Kulke,David P. Ryan +16 more
TL;DR: A two-cohort phase II study to evaluate the efficacy of cabozantinib in patients with advanced carcinoid or pNET found objective response rate as measured by RECIST 1.1.228.
Journal ArticleDOI
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro,Eunice L. Kwak,Bruce J. Dezube,Murray Yule,John Ayrton,John Lyons,Daruka Mahadevan +6 more
TL;DR: AT13387 administered once or twice weekly has an acceptable safety profile and demonstrated evidence of target engagement and preliminary antitumor activity.
Journal ArticleDOI
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
Nils D. Arvold,David P. Ryan,Andrzej Niemierko,Lawrence S. Blaszkowsky,Eunice L. Kwak,Jennifer Y. Wo,Jill N. Allen,Jeffrey W. Clark,Raymond C. Wadlow,Andrew X. Zhu,Carlos Fernandez-del Castillo,Theodore S. Hong +11 more
TL;DR: Neoadjuvant chemotherapy before chemoradiation therapy (CRT) may improve outcomes for patients with locally advanced pancreatic cancer, but optimal management remains controversial, and prior reports have limited follow‐up.
Journal ArticleDOI
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
Theodore S. Hong,David P. Ryan,Lawrence S. Blaszkowsky,Harvey J. Mamon,Eunice L. Kwak,Mari Mino-Kenudson,Judith Adams,Beow Y. Yeap,Barbara Winrich,Thomas F. DeLaney,Carlos Fernandez-del Castillo +10 more
TL;DR: Preoperative chemoradiation with 1 week of proton beam therapy and capecitabine followed by early surgery is feasible and a Phase II study is underway.